- 1 Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a,
- 2 double-blind, randomised, controlled phase 3 trial
- 3

4 **Supplementary Materials**

5	Table 1. The COVAXIN Study Group	page 2
6	Reverse transcription polymerase chain reaction (RT-PCR)	page 5
7	Enzyme-linked immunosorbent assay (ELISA) at Screening	page 6
8	Enzyme-linked immunosorbent assay (ELISA) for lot-to-lot comparisons	page 6
9	Next-Generation Sequencing method	page 7
10	Microneutralisation method	page 8
11	ELISA Assays for S1 protein, RBD and N-antigen of SARS-COV-2	page 9
12	Table 2. Participants disposition status	page 10
13	Figure 1. Geometric mean ratios of MNT_{50} for three consecutive vaccine lots	page 11
14	Table 3. Geometric mean MNT_{50} by age, gender and baseline serostatus	page 12
15	Table 4. Summary of adverse events	page 13
16	Table 5. Incidences of solicited adverse events after each dose	page 14

Supplementary table 1: CC	VAXIN Study Grou	up and Ethic Commit	tees	s from all participating tri	al s	ites
Hospital Name, City, State	Ethics Committee Number	Principal Investigator		Co-Principal Investigator		Study Coordinators/Field Worker/Nurse
Lokmanya Tilak Municipal Medical College and General Hospital, Mumbai, Maharashtra	ECR/175/Inst/M H/2013/RR-19	Nilkanth Awad, MD	1) 2) 3)	Siddharth Waghmare, MD Vaibhav Aglawe, MD Jairaj Nair, MD	1) 2) 3) 4) 5)	Bhavika Jain Chaitali Babar Poonam Kabale Akash Dhoble Ankur Humare
Grant Government Medical College and Sir J.J Group of Hospitals, Mumbai, Maharashtra	ECR/382/Inst/M H/2013/RR-19	Priti Meshram, MD	1) 2) 3)	Dinesh Dhodi, MD Manali Vable, MD Archana Bandkar, MD	1) 2) 3) 4) 5)	Mehul Shah Zainab Shaikh Sabir Khan Alex Pandit Smruti Chalke
People's College of Medical Sciences and Research Centre And Associated People's Hospital, Bhopal, Madhya Pradesh	ECR/519/Inst/M P/2014/RR-17	Raghvendra Gumashta, MD	1) 2) 3)	Sushil Jindal, MD Chittaranjan Chaubal, MD Sanjay Tandon, MD	1) 2) 3) 4)	Saroj Mani Anjlika Jhariya Namrata Manjhi Richa Jain
Nizam's Institute of Medical Sciences, Punjagutta Market, Hyderabad	ECR/303/INST/A P/2013/RR-19	Prabhakar Reddy, MD	1) 2) 3)	Ruby Raphael, MD V Bhavani, MD Abid Ali, MD	1) 2)	G. Devika Lanka Tejaswi
Gujarat Medical Education and Research Society Medical College and Civil Hospital, Sola, Ahmedabad, Gujarat	ECR/404/Inst/GJ /2013/RR-20	Parul Bhatt, MD	1) 2) 3)	Kiran Rami, MD Rashmi Sharma, MD Meera Shah, MD	1) 2) 3) 4) 5)	Smruti Parekh Vaishali Chauhan Viraj Salvi Anuj Tarpara Dhaval Kumpavat
Indian Council of Medical Research, National Institute of Cholera and Enteric Diseases, Kolkata, West Bengal	ECR/416/Inst/W B/2013/RR-20	Suman Kanungo, MD	1) 2) 3)	Shanta Dutta, MD Agniva Majumdar, MD Jaayanta Saha, MBBS	1) 2) 3) 4) 5)	Snehasish Saha Rupesh Mishra Abhijit Guha Dipak Das Arpan Mitra
Institute of Medical Sciences and SUM Hospital, Bhubaneshwar, Odisha	ECR/627/Inst/O R/2014/RR-17	Venkat E Rao, MD	1) 2) 3)	Jyotiranjan Sahoo, MD Smaraki Mohanty, MD Sandeep Kumar Panigrahi, MD	1) 2) 3) 4) 5)	Sahazad Ali Banajini Pradhan Manini Sahoo Perween Sultana Binata Samal
All India Institute of Medical Sciences, Patna, Bihar	ECR/1387/INST/ BR/2020	Chandramani Singh, MD	1) 2) 3)	Sanjay Pandey, MD Pragya Kumar, MD Yogesh Kumar, MD	1) 2) 3) 4)	Sarvesh Singh Nitin Kr Singh Achal Singh Shreekant Kumar
Jeevan Rekha Hospital, Belgaum, Karnataka	ECR/1242/INST/ KA/2019	Amit Bhate, MD	1) 2) 3)	Suresh Bhate, MD Paritosh Desai, MD Abhishek Chavan, MD	1) 2) 3) 4) 5)	Ajay Kunal Imran Mulla Sameer Nadaf Laxman Arabhavi Shoiab Shaikh
SRM Medical College and Research Centre, SRM	ECR/431/INST/T L/2013/RR-19	Satyajit Mohapatra, MD	1) 2)	Melvin George, MD Balaji Ramraj, MD	1) 2) 3)	Tharunya Palanivel Kalai Selvi Indiraa Priyadarshini

Nagar, Kattankulathur,			3)	Gayathri	4)	Kamatchi
Tamilnadu				Balasubramaniyam, MD	5)	Anusuya
All India Institute of Medical					1)	Shreya Jha,
Sciences, Patna, New Delhi			1)	Pandoon Culoria MD	2)	Suprakash Mandal
	ECR/547/INST/D		1)	Randeep Guleria, MD	3)	Tripti Rai
	L/2014/RR-17	Sanjay Rai, MD	2)	Shashi Kant, MD	4)	Priyanka Bansal
			3)	Praveen Aggarwal, MD	5)	Akshay Sharma
					6)	Kirti Diswar
Prakhar Hospital, Kanpur,					1)	Nidhi Singh
Uttar Pradesh			1)	V Tripathi, MD	2)	Astha Singh
	ECR/1017/INST/	Jitendra Singh, MD	2)	Vikas Mishra, MD	3)	Saumya Singh
	UP/2017		3)	Anit Singh, MD	4)	Sandeep Uniyal
			-,		5)	Dev Chaudhary
Rahate Surgical Hospital and					1)	Ashish Tajne
ICU, Nagpur, Maharashtra					2)	Vaishali Tajne
	ECR/601/Inst/M	Manish Multani,	1)	Prashant Rahate, MS	3)	Vrushali Mohitkar
	H/2014/RR-17	MD	-/		4)	Pravina Lanjewar
					5)	Megha Balbudhe
Vudabi Instituta of Madical					1)	Nripesh Nepal
Vydehi Institute of Medical			1)	Gummadi Reddy, MD	2)	Khushboo Sharma
Sciences and Research,	ECR/747/Inst/KA	Akshatha Savith,	2)	Chalapathy DV, MD	2) 3)	Hasina Taj
Bengaluru, Karnataka	/2015/RR-18	MD	3)	Natesh Rao, MD	3) 4)	Arun Kumar
					4) 5)	Payel Sarkar
					-	
Mahatma Gandhi Medical			1)	Lokesh Shanmugam, MD	1)	Kowshik Reddy Subashri R
College and Research	ECR/451/Inst/PO	Pajanivel		-	2)	
Institute, Pondicherry, Tamilnadu	/2013/RR-19	Ranganadin, MD	2)	Vimal Raj, MD	3)	Soundariya Selva Pandian
Taminadu					4) 5)	
					5)	Agnus Panikar
Redkar Hospital and				Mush Dadhar MD	1)	Tejaswini Patil
Research Centre, Pernem,	ECR/902/INST/G		1)	Vivek Redkar, MD	2)	Mrunali Desai
Goa	A/2018	Sagar Redkar, MD	2)	Supriya Redkar, MD	3)	Sarvesh Kerkar
			3)	Shraddha Rane, MD	4)	Jyoti Patil
					5)	Dhananjay Lad
ESIC Medical College and			1)	Pooja Goyal, MD	1)	Dr. Bharti Gaur
Hospital, Haryana	ECR/167/Inst/HR		2)	Nidhi Anand, MBBS	2)	Neha Katiyar
	/2013/RR-19	Anil Pandey, MD	3)	Kranti Garg, MD	3)	Soniya Chahal
	//		5,		4)	Ayona James
					5)	Mohit Prajapati
Directorate of Public Health					1)	Savitha Balaji
and Preventive Medicine,	ECR/270/		1)	Palani Sampath, MBBS	2)	Roshini Azhaguvel
Chennai, Tamilnadu	Inst/TN/2013/RR	Selvavinayagam	2)	Sudharshini	3)	Parasuraman
	-16	Sivaprakasam, MD		Subramaniam, MD		Palanivel
	10				4)	Sangliraj Muthukalai
					5)	Ayesha Bee
Sir Ganga Ram Hospital,					1)	Ajeet Nanda
New Delhi, Delhi		Anunam Cachdau-	1)	Manas Kalra, MD	2)	Vinay Sharma
	ECR/20/INST/DL /2013/RR-19	Anupam Sachdeva, MD	1)		3)	Rajni Singh
	/2013/11-19	טוא	2)	Pooja Khosla, MD	4)	Sakshi Pandey
					5)	Priyanka Singh
Maharaja Agrasen Hospital,	ECR/745/INST/D		1)	Prabhat Sharma, MD	1)	Kapil Soni
Jaipur, Rajasthan	L/2015/RR-18	Manish Jain, MD	2)	Deepak Sharma, MBBS	2)	Khushwant Khatri
· -	, -,		-/		-/	

			3)	Madhvender Jain, MD	3)	Sanjeev Vimal
					4)	Gaurav Dalvi
					5)	Preshita Vanjare
Pandit Bhagwat Dayal					1)	Deepak Gill
Sharma Post Graduate			1)	Dhruva Chaudhary, MD	2)	Anjali Ahlawat
Institute of Medical	ECR/293/Inst/HR	Savita Verma, MD	2)	Ramesh Verma, MD	3)	Kavita
Sciences, Rohtak, Haryana	/2013/RR-19		3)	Pawan Singh, MD	4)	Bijender Singh
			,	0,	5)	Rosy
Government Fever Hospital,					1)	Krishna Suri
Gorantla, Guntur					2)	Durga Anjali
	ECR/467/Inst/AP	S Laxmikumari, MD	1)	D Sudheer, MD	, 3)	G Divya
	/2013/RR-19	,	2)	P Basha, MD	4)	K Sowmya
					5)	K Jyothi
Aligarh Muslim University,					1)	Mohammad Shiraz
Aligarh, Uttar Pradesh					1) 2)	Azimuddin Malik
Aligani, Ottai i radesh	ECR/1418/	Mohammad			2) 3)	Shafeequr Rahman
	Inst/UP/2020	Shameem, MD	1)	Mansoor Tariq, MS	3) 4)	Nafees Khan
	11130/01/2020	Shameen, we			4) 5)	Samia Kirmani
					5,	Janna Kirmani
Prakash Institute of Medical						
Science and Research,	ECR/1052/Inst/	Vijaykumar Patil,	1)	Pradeep Kulkarni, MBBS	1)	Vishwajit Khade
Islampur, Sangli,	MH/2018	MD	4)	B Patil, MD	2)	Heyeshi Singh
Maharashtra	,		.,		3)	Suhash Thorat
Rajashree Chhatrapati					1)	Ratnadeep Patil
Shahu Maharaj Government	FCD /702 /		1)	Vijay Barge, MD	1) 2)	Shivani Patil
medical college and	ECR/703/ Inst/MH/2015/R	Sunita Ramanand,	2)	Varun Bafna, MD		
Chhatrapati Pramila Raje	R-20	MD			3)	Suraj Shewale Sadhana Jadhav
Hospital, Kolhapur,	N-20		3)	Rama Bhosale, MD	4) 5)	
Maharashtra					5)	Nupur Shevale
Bharat Biotech Clinical Team:			ICI	MR-National Institute of Vi	rolo	<u>gy:</u>
Shashi Kanth Muni, BDS			An	ita Shete-Aich, PhD		
Sapan Kumar Behera, MD			Gu	ıruraj Deshpande, PhD		
Yuvraj Jogdand, MD			Dr	. Vinita Malik, PhD		
Bhargav Reddy Dalta, PharmD			Mr	rs. Sheetal Kadam, MSc		
Mr. Sunil Kumar Kantheti			Pro	of. (Dr.) Priya Abraham, MD	, Phi	D
Ms. Sandhya Rani Nandala						
Ms. Aparna Bathula			Inc	dian Council of Medical Res	earc	<u>:h:</u>
Ms. Amaravani Pittala			Sa	miran Panda, PhD		
Mr. Little Master Reddy			Sw	vati Gupta, PhD		
Mr. Ashok Sudamala						
Mr. Nagaraju Pillutla						
Mr. Hrishikesh Reddy						
Ms. Akhila Naidu						

20 Reverse transcription polymerase chain reaction (RT-PCR)

- 21 The ICMR-NIV 2019-nCoV Assay Kit 3.1 contains a set of TaqMan RT-PCR assay for the qualitative
- 22 detection and characterisation of SARS-CoV-2 RNA. The assay kit uses TaqMan Fluorogenic probe-
- 23 based chemistry that uses the 5' nuclease activity of Taq DNA polymerase and enables the detection
- 24 of a specific PCR product as it accumulates during PCR cycles.
- 25 The assay includes three targets E gene, ORF 1ab, RdRp of SARS-CoV-2 genes, and one house keeping
- 26 gene, the β-Actin gene. The assay has one screening and two confirmatory viral genomic region
- 27 targets, reducing the risk of false negatives.
- 28 The assay runs for 40 cycles; however, for any interpretation, the threshold cut off cycle Ct is 35.

29 **Results Interpretation is as follows:**

Target	E	ORF	RdRp	β-Actin
Positive	+	+	+/-	+
Negative	-	-	-	+
Strong* Positive (Very low Ct)	+	+	+	-
Sample quality poor	-	-	-	-
Inconclusive	+	-	-	+

31	Enzyme-linked immunosorbent assay (ELISA) at Screening
32	The National Institute of Virology (NIV) SARS-CoV-2 Human IgG ELISA kit is intended for qualitative
33	detection of IgG antibodies in serum/plasma of patients presenting clinical signs and symptoms
34	consistent with SARS CoV-2 infection or recovered patients. The sensitivity of the assay is 97.9%
35	percent and specificity 92.3% percent for Laboratory routine testing.
36	Each kit contains one vial of "Positive control" and one vial of "Negative control". These work as
37	markers of kit performance. P/N ratio of Positive control is defined as ratio of OD value of Positive
38	control divided by OD of average OD of Negative control. The test is considered to be valid if P/N
39	ratio is greater than 1.5.
40	Results are interpreted as follows:
41	• For an unknown sample (test sample) if O.D. value > Cutoff value and P/N ratio more than
42	1.5, sample should be considered as "Positive".
43	• For an unknown sample (test sample) if O.D. value < Cutoff value and P/N ratio less than 1.5,
44	sample should be considered as "Negative".
45	
46	Enzyme-linked immunosorbent assays (ELISA) done at Bharat Biotech for lot-to-lot comparisons
47	ELISA tests were performed as per standard protocols. Briefly, microtiter plates were coated with
48	SARS-CoV-2 specific antigens: Whole inactivated SARS CoV-2 antigen; spike (S1) (Syngene,
49	Bangalore, India, Batch No# PRB026913); Receptor Binding Domain (RBD) (Syngene, Bangalore,
50	India, Batch No#PRB025485); nucleocapsid (N) (Syngene, Bangalore, India, Batch No# PRB025627) at
51	a concentration of 1µg/ml, 100µl/well in PBS pH 7·4). After overnight incubation, wells were blocked
52	and serially diluted sera added. After incubation, goat anti-Human IgG HRP conjugate (Sigma-Aldrich,
53	Cat# A8667, dilution 1:5000) was added and incubated for 1 hr at RT. Tetramethyl benzidine was
54	used as a substrate and absorbance measured at 450/630nm. Threshold value (Mean + 3 SD) was
55	established by taking the absorbance of Day 0 sera and antigen-specific endpoint titers were
56	determined for Day 56 sera samples. The reciprocal antibody dilution, at which absorbance is above
57	the threshold, was taken as antigen-specific antibody endpoint titers. All methods were validated
58	with respect to sensitivity and specificity.
59	Known unvaccinated and uninfected individual sera were used as a negative controls.
60	Simultaneously, ELISA blank (without coating antigen) was also maintained as a negative control.
61	Apart from this, cut off (Mean+3 SD) was drawn from the absorbance obtained at various dilutions
62	(1:1000 to 1:32000) of sera collected on day 0 (before vaccination) which had been found negative
63	in the RT-PCR and serology tests.

64 Next-Generation Sequencing

- 65 We were able to collect additional Nasopharyngeal swabs (NP) swabs from symptomatic Covid-19
- 66 (diagnosed by RT-PCR) participants who provided additional consent. All of the sequences were
- 67 generated by the ICMR-National Institute of Virology (NIV), Pune, India using a next-generation
- 68 sequencing approach. Controls were checked to ensure no evidence of amplification in the negative
- 69 tests and that expected RNA quantification was consistent with cycle threshold (Ct) values provided
- 70 by the testing laboratories.
- All samples were processed by NIV laboratory staffs who were masked to vaccine allocation. In brief,
- the total RNA was extracted from 200-400 μl of the SARS-CoV-2 real-time RT-PCR positive samples.
- 73 Extracted RNA was quantified using a Qubit RNA High Sensitivity (HS) kit by Qubit[®] 2.0 Fluorometer
- 74 (Invitrogen, Life Technologies). Samples having CT values below 25 were selected for further
- 75 processing with NGS. A total of 208 primers (104 for Pool#1 and 104 for Pool #2) were designed
- vising the Primal Scheme online tool covering the entire genome of the SARS-CoV-2. A multiplex RT-
- PCR using the Superscript IV PCR kit (Invitrogen) was performed under the following conditions: 50°C
- for 30 min; 98°C: 2 min; 35 cycles of 98°C for 10 sec, 56°C for 100 sec, and 72°C for 30 sec and final
- 79 extension at 72°C for 5 min. The PCR products obtained were loaded (25 μl) onto a 2% Agarose gel
- 80 and checked for the presence of a PCR product of the desired size.
- 81 Bands of around 400 bp were observed in all the Pool 1 and Pool 2 PCR products of samples. Gel
- 82 extraction of DNA bands was performed using the QIA quick DNA extraction kit protocol. This gel-
- 83 purified DNA product was used for the library preparation from the A-tailing step by Illumina Truseq
- 84 LT kit as described earlier (Nyayanit et al, 2020; Yadav et al, 2021). Libraries were quantified using
- 85 KAPA Library Quantification Kit (Kapa Biosystems, Roche Diagnostics Corporation, USA). Equimolar
- 86 ratios of libraries were pooled and denatured with 0.1 N NaOH and were neutralised using 0.1 M Tris
- 87 (pH7·0). The denatured libraries were diluted to 1·3 picomole using hybridization buffers before
- 88 loading onto Illumina Next seq 550 mid-outputs 300 cycles' reagent cartridges. CLC genomics
- 89 workbench version11.0 (CLC, QIAGEN, and Germany) was used for the analysis of the data
- 90 generated from the machine. Reference-based mapping was performed to retrieve the sequence of
- 91 the SARS-CoV-2.
- 92 Nyayanit DA, Sarkale P, Baradkar S, et al. Transcriptome & viral growth analysis of SARS-CoV-2-
- 93 infected Vero CCL-81 cells. Indian J Med Res 2020; 152:70–6.
- 94 Yadav PD, Potdar VA, Choudhary ML, et al. Full-genome sequences of the first two SARS-CoV-2
- 95 viruses from India. Indian J Med Res 2020; 151: 200–9.

- 96 Microneutralisation immunogenicity assay method (MNT₅₀)
- 97
- 98 A microneutralisation assay (MNT₅₀) was done at Bharat Biotech for the immunological lot to lot

99 comparisons.

- 100 The sera collected from all enrolled participants were inactivated at 56°C in a water bath for 30 min.
- 101 Sera were successively diluted in a two-fold series from a starting dilution of 1:8 to the required
- 102 concentration, and an equal volume of challenge virus solution containing 100 CCID₅₀ viruses was
- 103 added. After neutralisation in a 37°C incubator for two hours, a 1.0 x 10⁵ /mL cell suspension was
- added to the wells (0.1 mL/well) and cultured in a CO₂ incubator at 37°C for 3–5 days. The method
- 105 of Ramakrishnan (2016) was used applied to observations of the cytopathic effect (CPE) to
- 106 calculate the neutralisation endpoint (MNT₅₀) converting to logarithm the serum dilution that
- 107 protects 50% of cells from infection by challenge with 100 $CCID_{50}$ virus.
- 108
- 109 During each assay, a known antibody titre is used as a positive control, and pre-immune sera are
- 110 used as a negative control.
- 111
- 112 Ramakrishnan MA. Determination of 50% endpoint titer using a simple formula. World J Virol 2016;
- 113 *5:85–6*.
- 114

115 ELISA assays for IgG against SARS-Cov-2 epitopes

- 116 The National Institute of Virology (NIV) SARS-CoV-2 Human IgG ELISA kit is intended for qualitative
- 117 detection of IgG antibodies in serum/plasma of patients presenting clinical signs and symptoms
- 118 consistent with SARS CoV-2 infection or recovered patients. The sensitivity of the assay is 97.9%
- 119 percent and specificity 92.3% percent for Laboratory routine testing.
- 120 Each kit contains one vial of "Positive control" and one vial of "Negative control". These work as
- 121 markers of kit performance. P/N ratio of Positive control is defined as ratio of OD value of Positive
- 122 control divided by OD of average OD of Negative control. The test is considered to be valid if P/N
- 123 ratio is greater than 1.5.
- 124 Results are interpreted as follows:
- For an unknown sample (test sample) if O.D. value > Cutoff value and P/N ration more than
 126
 1.5, sample should be considered as "Positive".
- For an unknown sample (test sample) if O.D. value < Cutoff value and P/N ration less than
 1.5, sample should be considered as "Negative".
- 129 Enzyme-linked immunosorbent assays (ELISA) done at Bharat Biotech for lot-to-lot comparisons
- 130 ELISA tests were performed as per standard protocols. Briefly, microtiter plates were coated with
- 131 SARS-CoV-2 specific antigens: Whole inactivated SARS CoV-2 antigen; spike (S1) (Syngene,
- 132 Bangalore, India, Batch No# PRB026913); Receptor Binding Domain (RBD) (Syngene, Bangalore,
- 133 India, Batch No#PRB025485); nucleocapsid (N) (Syngene, Bangalore, India, Batch No# PRB025627) at
- 134 a concentration of 1µg/ml, 100µl/well in PBS pH 7·4). After overnight incubation, wells were blocked
- 135 and serially diluted sera added. After incubation, goat anti-Human IgG HRP conjugate (Sigma-Aldrich,
- 136 Cat# A8667, dilution 1:5000) was added and incubated for 1 hr at RT. Tetramethyl benzidine was
- 137 used as a substrate and absorbance measured at 450/630nm. Threshold value (Mean + 3 SD) was
- 138 established by taking the absorbance of Day 0 sera and antigen-specific endpoint titers were
- 139 determined for Day 56 sera samples. The reciprocal antibody dilution, at which absorbance is above
- 140 the threshold, was taken as antigen-specific antibody endpoint titers. All methods were validated
- 141 with respect to sensitivity and specificity.
- 142 Known unvaccinated and uninfected individual sera were used as a negative controls.
- 143 Simultaneously, ELISA blank (without coating antigen) was also maintained as a negative control.
- 144 Apart from this, cut off (Mean+3 SD) was drawn from the absorbance obtained at various dilutions
- 145 (1:1000 to 1:32000) of sera collected on day 0 (before vaccination) which had been found negative
- 146 in the RT-PCR and serology tests.

Description	BBV152 (N=12,899) n (%)	Placebo (N=12,899) n (%)	Total (N=25,798) n (%)
Screened Participants			26028
Screen Failure			217
Screened but not enrolled			13
Enrolled Participants	12899 (100)	12899 (100)	25798 (100)
Ongoing Participants	12194 (94·5)	12063 (93·5)	24257 (940)
Randomisation Analysis Set ^a	12899 (100)	12899 (100)	25798 (100)
Full Analysis Set (FAS) ^b	8946 (69·4)	8988 (69·7)	17934 (69·5)
Per-protocol Analysis Set (PP) ^c	8471 (65·7)	8502 (65·9)	16973 (65·8)
Immunogenicity Analysis Subset ^d	428 (3.3)	141 (1.1)	569 (2·2)
Safety Analysis Set ^e	12879 (99·8)	12874 (99·8)	25753 (99·8)
Category of Site			
Category 1 (Symptomatic)	8102 (62·8)	8375 (64·9)	16477 (63·9)
Category (Symptomatic/Asymptomatic)	4348 (33·7)	4373 (33·9)	8721 (33·8)
Category 3 (Symptomatic/Asymptomatic + Immunogenicity)	449 (3·5)	151 (1·2)	600 (2·3)
Visit 1 Completed	12,899 (100)	12,899 (100)	25,798 (100)
Visit 2 Completed	12,310 (95·4)	12,310 (95·4)	24,620 (95·4)
Visit 3 Completed	12,054 (93·5)	12,086 (93·7)	24,140 (93·6)
Visit 4 Completed	11,909 (92·3)	11,893 (92·2)	23,803 (92·3)

147 (a) All randomised participants classified according to the study product (vaccine or placebo) to which they148 were randomised.

(b) All randomised participants who received at least one dose of IP and had no immunologic evidence of prior
 COVID-19 (i.e, negative against SARS-CoV-2 antibodies) at Visit 1 before the first dose of IP. Participants will
 be analysed according to the study product (vaccine or placebo) received.

(c) All participants in the FAS who received planned doses of IP per schedule, seronegative for SARS-CoV-2
 antibody by ELISA at baseline, and had no major protocol deviations, as determined, and documented by
 the Sponsor.


(d) Designated participants at study sites included in the immunogenicity study (category 3) who had receivedboth doses of IP and had no major protocol deviations.

(e) The Safety Set consists of all randomised participants who received at least one dose of IP, classifiedaccording to the study product received.

159 % = n/N * 100 where N = number of enrolled participants and n = number of participants.

160 Database cut-off date: 17 May 2021

161 Figure 1. Geometric mean ratios of MNT_{50} for three consecutive manufacturing lots of BBV152 162



GMT ratio (95% CI)

163 164

165 Lot-to-lot consistency between treatments was declared if for all lot-to-lot comparisons, the two-

166 sided 95% CI for the GMC ratio was completely contained within 0.5 and 2.0.

MNT ₅₀			BBV152 (All lots) (N = 386)	Placebo (N = 119)		
		n GMT (95% CI)		n	GMT (95% CI)	
Age Group	≥18–<60	334	129.9 (114.3, 147.6)	101	12.9 (10.1, 16.5)	
(years)	≤60	52	101.2 (70.0, 146.3)	18	19.1 (9.0, 40.5)	
Male Gender Female		238	118.2 (101.0, 138.3)	77	14.1 (10.4, 19.2)	
		148	138.4 (114.4, 167.3)	42	12.9 (8.8,19.0)	
SARS-CoV-2	Negative	338	118.03 (104.0, 134.0)	99	11.9 (9.3,15.2)	
lgG status at baseline	Positive	48	194.3 (134.4, 280.9)	20	27.4 (14.0, 53.5)	

169 Shown are geometric mean titres measured using the wild-type SARS-CoV-2 microneutralisation

170 assay (MNT_{50}) in sera obtained at Day 56, 4 weeks after the second vaccination.

171

172

168

Г

Supplementary table 4. Sum	mary of a	dverse events				
	В	BV152	Р	lacebo	٦	Fotal
	(N	= 12,879)	(N =	= 12,874)	(N =	25,798)
	Events	Participants	Events	Participants	Events	Participants
	n	n (%)	n	n (%)	n	n (%)
All Adverse Events	2930	1597 (12·4)	3029	1597 (12·4)	5959	3194 (12·4)
Solicited AEs						
Any solicited AE	1949	1223 (9·5)	1720	1136 (8∙8)	3669	2359 (9·2)
Solicited AE within 7 days post dose 1	1151	809 (6·3)	994	702 (5·5)	2145	151 (5·9)
Solicited AE within 7 days post dose 2	798	568 (4·4)	726	548 (4·3)	1524	1116 (4·3)
Unsolicited AEs	981	489 (3·8)	1309	609 (4·7)	2290	1098 (4·3)
Serious Adverse Events	40	39 (0·30)	66	60 (0·47)	106	99 (0·38)
All Medically Attended Adverse Events (MAAEs)	475	301 (2·3)	548	319 (2·5)	1023	620 (2·4)
Immediate AEs (within 30 min post vaccination)						
Any immediate AE	14	12 (0∙10)	29	23 (0·18)	43	35 (0∙14)
Immediate AEs post dose 1	11	10 (0∙08)	19	17 (0∙13)	30	27 (0·10)
Immediate AEs post dose 2	3	3 (0∙02)	10	8 (0·06)	13	11 (0·04)
All Adverse Events of Special Interest (AESI)	23	23 (0·18)	23	23 (0·18)	46	46 (0·18)

174 N = number of participants in the relevant population,

175 Events, n = number of individual events reported (one participant may have reported several AEs),

176 Participants, n = Number of participants reporting at least one event,

177 % = n participants with an event/N *100

	BBV	/152	Plac	ebo	То	tal	
Participants reporting	(N = 1	2,879)	(N = 1	2,874)	(N = 25,798)		
solicited AEs within 7 days of vaccination, n(%)	Dose 1	Dose 2	Dose 1	Dose 2	Dose 1	Dose 2	
•	n (%)	n (%)					
Any Local AE	431	278	399	260	830	538	
	(3∙35)	(2·16)	(3·10)	(2·02)	(3·22)	(2·09	
Pain	392	233	358	208	750	441	
	(3·04)	(1·81)	(2·78)	(1·62)	(2·91)	(1·71)	
Erythema	33	21	26	25	59	46	
	(0·26)	(0∙16)	(0·20)	(0·19)	(0·23)	(0∙18)	
Induration	32	18	26	18	58	36	
	(0·25)	(0·14)	(0·20)	(0·14)	(0·23)	(0∙14)	
Swelling	21	14	32	16	53	30	
	(0∙16)	(0·11)	(0·25)	(0·12)	(0·21)	(0∙12)	
Any Systemic AE	331	231	247	205	578	436	
	(2·57)	(1·79)	(1·92)	(1·59)	(2·24)	(1·69)	
Pyrexia	108	86	81	79	189	165	
	(0·84)	(0·67)	(0·63)	(0·61)	(0·73)	(0∙64)	
Fatigue	52	41	41	20	93	61	
	(0·40)	(0·32)	(0·32)	(0·16)	(0·36)	(0·24)	
Chills	28	9	22	16	50	25	
	(0·22)	(0·07)	(0·17)	(0∙12)	(0·19)	(0∙10)	
Headache	128	86	111	70	239	156	
	(0·99)	(0·67)	(0·86)	(0·54)	(0·93)	(0∙61)	
Myalgia	49	37	28	28	77	65	
	(0·38)	(0·29)	(0·22)	(0·22)	(0·30)	(0·25)	
Arthralgia	17	12	17	17	34	29	
	(0·13)	(0·09)	(0·13)	(0·13)	(0∙13)	(0·11)	
Nausea	17	14	12	10	29	24	
	(0·13)	(0·11)	(0·09)	(0·08)	(0·11)	(0∙09)	
Vomiting	12	6	8	8	20	14	
	(0·09)	(0·05)	(0·06)	(0·06)	(0·08)	(0∙05)	

179 N = number of participants in the relevant population,

180 Events, n = number of individual events reported (one participant may have reported several AEs),

181 Participants, n = Number of participants reporting at least one event,

182 % = n participants with an event/N*100

183 Med